Journal Of Chemotherapy

Journal Of Chemotherapy

化疗杂志

  • 4区 中科院分区
  • Q3 JCR分区

期刊简介

《Journal Of Chemotherapy》是由Maney Publishing出版社于1989年创办的英文国际期刊(ISSN: 1120-009X,E-ISSN: 1973-9478),该期刊长期致力于传染病学领域的创新研究,主要研究方向为医学-药学。作为SCIE收录期刊(JCR分区 Q3,中科院 4区),本刊采用OA未开放获取模式(OA占比0.0468...%),以发表传染病学领域等方向的原创性研究为核心(研究类文章占比81.16%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在69篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Journal Of Chemotherapy审稿周期约为 较慢,6-12周 。该刊近年未被列入国际预警名单,年发文量约69篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 69 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
INFECTIOUS DISEASES 传染病学 ONCOLOGY 肿瘤学 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
INFECTIOUS DISEASES 传染病学 ONCOLOGY 肿瘤学 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:INFECTIOUS DISEASES SCIE Q3 90 / 132

32.2%

学科:ONCOLOGY SCIE Q3 234 / 322

27.5%

学科:PHARMACOLOGY & PHARMACY SCIE Q3 231 / 354

34.9%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:INFECTIOUS DISEASES SCIE Q3 82 / 132

38.26%

学科:ONCOLOGY SCIE Q3 208 / 322

35.56%

学科:PHARMACOLOGY & PHARMACY SCIE Q3 236 / 354

33.47%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:3.7 SJR:0.439 SNIP:0.531
学科类别 分区 排名 百分位
大类:Medicine 小类:Pharmacology (medical) Q3 139 / 272

49%

大类:Medicine 小类:Infectious Diseases Q3 181 / 344

47%

大类:Medicine 小类:Oncology Q3 228 / 404

43%

大类:Medicine 小类:Pharmacology Q3 186 / 313

40%

期刊发文

  • Using Monte Carlo simulation to determine optimal dosing regimen for cefetamet sodium for injection.

    Author: Li C, Sun J, Miao J, Qin Y, Wang Y, Yu R, Xiao Y.

    Journal: J Chemother. 2016 Jun;28(3):172-9. doi: 10.1179/1973947814Y.0000000214.

  • Efficacy and safety of biapenem in treatment of infectious disease: a meta-analysis of randomized controlled trials.

    Author: Pei G, Yin W, Zhang Y, Wang T, Mao Y, Sun Y.

    Journal: J Chemother. 2016 Feb;28(1):28-36. doi: 10.1179/1973947814Y.0000000226.

  • NOB1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer.

    Author: Liu K, Chen HL, Gu MM, You QS.

    Journal: J Chemother. 2016 Jun;28(3):225-9. doi: 10.1179/1973947815Y.0000000041. Epub 2016 May 31.

  • Radiotherapy combined with chemotherapy versus radiotherapy alone for early stage nasal natural killer/T-cell lymphoma: a meta-analysis.

    Author: Zhang B, Zhu F, Liu X, Zhao J, Li M, Li Y, Huang J, Zou L, Chang Q.

    Journal: J Chemother. 2016 Feb;28(1):65-71. doi: 10.1179/1973947815Y.0000000035.

  • PQ401, an IGF-1R inhibitor, induces apoptosis and inhibits growth, proliferation and migration of glioma cells.

    Author: Zhou X, Zhao X, Li X, Ping G, Pei S, Chen M, Wang Z, Zhou W, Jin B.

    Journal: J Chemother. 2016 Feb;28(1):44-9. doi: 10.1179/1973947815Y.0000000026.

  • Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI).

    Author: Tseng YH, Hung HY, Sung YC, Tseng YC, Lee YC, Whang-Peng J, Chen YM.

    Journal: J Chemother. 2016 Feb;28(1):50-8. doi: 10.1179/1973947815Y.0000000027.

  • Neoadjuvant chemotherapy in controlling lymph node metastasis for locally advanced gastric cancer in a Chinese population.

    Author: Dong S, Yu JR, Zhang Q, Liu XS.

    Journal: J Chemother. 2016 Feb;28(1):59-64. doi: 10.1179/1973947815Y.0000000028.

  • In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase.

    Author: Wei W, Yang H, Liu Y, Ye Y, Li J.

    Journal: J Chemother. 2016 Jun;28(3):159-63. doi: 10.1179/1973947815Y.0000000030. Epub 2016 Apr 22.